Top 9 posts you dont wanna wiss from WCLC
The 2023 World Conference on Lung Cancer took place in Singapore from September 9-12. Our team at OncoDaily has collected 9 posts from WCLS 2023.
1. Estela Rodriguez, Co-Lead Thoracic Site Disease Group at Sylvester Comprehensive Cancer Center
Practice changing? FLAURA2 RCT of osimertinib + chemo vs. osimertinib alone presented by Dr. Pasi Janne.
Favoring osimertinib + chemo as 1L therapy for EGFR NSCLC.
-N= 557
-Increased PFS 25.5 vs 16.7 m.
-Overall survival (OS) data is not yet mature.
-Increased benefit in L858R.
-Increased chemo toxicity.
-Increased benefit in patients with CNS Mets.
8-month improvement in PFS can not be overlooked in young patients with other poor risk factors but OS awaited to change SOC.
Photo taken from Estela Rodriguez/Twitter
2. Chul Kim, Thoracic Medical Oncologist at Georgetown University
Defining oligometastatic disease (OM) is tricky: Is it by the number of sites or its biology? Both perspectives probably hold the answer. The timing and method of local ablative therapy differ across studies.
In low to middle-income regions, the challenges of treating OM include a skilled medical team, equipment, and comorbidities like tuberculosis. Proper patient selection through multi-D is vital.
Great talk by Dr. Tibdewal.
Photo taken from Chul Kim/Twitter
3. Hidehito Horinouchi, General Secretary of Lung Cancer Study Group, Japan Clinical Oncology Group
9th Edition TNM Staging Classification: Lung Cancer by Prof. Hisao Asamura. Huge shift to a surgically oriented treatment strategy! Very relevant renewal in the era of peri-ope ICIs and TKIs. Let’s prepare stage translation of peri-ope trials.
4. Rami Manochakian, Associate Professor and HemOnc Fellowship Director at Mayo Clinic
Hot off the press, presented by IASLC during WCLC23, results of ETER701, phase 3 trial of Benmelstobal + Anlotinib + Chemo vs Placebo + Chemo in 1st line therapy for extensive stage ES.
Unprecedented historical IMPROVEMENT in PFS and OS.
mPFS 6.9 vs 4.2 months
mOS 19.3 vs 11.9 months
5. Christine Lovly, Associate Professor of Medicine at Vanderbilt University
Lung cancer community – stop scrolling. Check this out!
Amazing!
Two pillars of the lung cancer world – David Carbone + David Gandara – will *match* all donations made to IASLC during WCLC2023 to help support young investigators. Please consider donating.
6. Annabelle Gurwitch, American author, comedic actress and television host
I think of myself as a giver, but I believe that I learned from Christian Rolfo that since liquid biopsy showed I’m not giving (circulating tumor) ctDNA to my bloodstream it means I might not be “a shedder” and that’s a good thing.
Photo taken from Annabelle Gurwitch/Twitter
7. Prunella Blinman, Clinical Associate Professor at Concord Repatriation General Hospital
Princess Dina Mired of Jordan opening the Gender Equity session.
Many pearls from her outstanding career as a global health advocate & mother of a cancer survivor.
– Mentorship is key
– You know enough
– You belong at the table
Thank you!
Photo taken from Prunella Blinman/Twitter
8. Narjust Florez, Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center
Family history of lung cancer in first-degree relatives was associated with higher LC detection rates than previous heavy tobacco use.
Female patients had higher prevalence of a family history of lung cancer.
9. Chul Kim, Thoracic Medical Oncologist at Georgetown University
Early detection program for lung cancer in Taiwan. Eligible populations: heavy smokers, individuals with a family history of lung cancer. The detection rate is highest among individuals with a familial history of the disease. Future directions for this program include incorporating AI-driven lung nodule detection and integrating smoking cessation services.
Crucial initiative. Is there a need for a randomized trial to determine the precise benefit in individuals with a family history of lung cancer?”
Photo taken from Chul Kim/Twitter